Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis

Journal of Infectious Diseases

Volumn 206, Issue 4, 2012, Pages 606-616

  Unsinger, Jacqueline ^a   Burnham, Carey Ann D ^a   McDonough, Jacquelyn ^a   Morre, Michel ^b   Prakash, Priya S ^b   Caldwell, Charles C ^b   Dunne, W Michael ^a   Hotchkiss, Richard S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RECOMBINANT INTERLEUKIN 7; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4; IMMUNOLOGIC FACTOR; INTERLEUKIN 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INVASIVE CANDIDIASIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CANDIDEMIA; DISEASE MODEL; IMMUNOLOGY; MICROBIOLOGY; MORTALITY; PATHOGENICITY; SEPSIS; TREATMENT OUTCOME;

ANIMALS; CANDIDA ALBICANS; CANDIDEMIA; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; INTERLEUKIN-7; MALE; MICE; MICE, INBRED C57BL; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866936380     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis383     Document Type: Article

References (49)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
2. Murphy SL. Deaths: final data for 1998. Natl Vital Stat Rep 1998; 48:1-105.
3. Monnert G, Venet F. Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past? Expert Rev Anti Infect Ther 2010; 8:1109-12.
4. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163:316-21.
5. Weighardt H, Heidecke CD, Emmanuilidis K, et al. Sepsis after major visceral surgery is associated with sustained and interferon-gammaresistant defects of monocyte cytokine production. Surgery 2000; 127:309-15.
6. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009; 15:496-7.
7. Venet F, Chung CS, Monneret G, et al. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008; 83:523-35.
8. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204:1463-74.
9. Luyt CE, Combes A, Deback C, et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007; 175:935-42.
10. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300:413-22.
11. Lipsett PA. Surgical critical care: fungal infections in surgical patients. Crit Care Med 2006; 34(suppl):S215-24.
12. Miceli MH, Dâiaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11:142-51.
13. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16:445-52.
14. Lepak A, Andes D. Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit Care Clin 2011; 27:123-47.
15. Romani L. The T cell response against fungal infections. Curr Opin Immunol 1997; 9:484-90.
16. Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect 2010; 16:1335-42.
17. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007; 7:144-54.
18. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174:6571-6.
19. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24:657-79.
20. Boyman O, Ramsey C, Kim DM, Sprent J, Surh CD. IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 2008; 180:7265-75.
21. Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol 2005; 26:56-64.
22. Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL. Interleukin- 7 restores immunity in athymic T-cell-depleted hosts. Blood 2001; 97:1525-33.
23. Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1:426-32.
24. Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010; 184:3768-79.
25. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330-42.
26. Rosenberg SA, Sportes C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-9.
27. Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205:1701-14.
28. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007.
29. Sereti I, Dunham RM, Spritzler J, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-14.
30. Pellegrini M, Calzascia T, Toe JG, et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011; 144:601-13.
31. Glocker E, Grimbacher B. Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Curr Opin Allergy Clin Immunol 2010; 10:542-50.
32. Romani L, Mencacci A, Cenci E, et al. An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol 1997; 158:2356-62.
33. Tschop J, Martignoni A, Reid MD, et al. Differential immunological phenotypes are exhibited following scald and flame burns. Shock 2008; 31:157-63.
34. Kasten KR, Prakash PS, Unsinger J, et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 2010; 78:4714-22.
35. Unsinger J, Herndon JM, Davis CG, Muenzer JT, Hotchkiss RS, Ferguson TA. The role of TCR engagement and activation-induced cell death in sepsis-induced T cell apoptosis. J Immunol 2006; 177:7968-73.
36. Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Inter Med 2009; 266:141-153.
37. Haraguchi N, Ishii Y, Morishima Y, et al. Impairment of host defense against disseminated candidiasis in mice overexpressing GATA-3. Infect Immun 2010; 78:2302-11.
38. Unsinger J, Kazama H, McDonough JS, Hotchkiss RS, Ferguson TA. Differential lymphopenia-induced homeostatic proliferation for CD4+ and CD8+ T cells following septic injury. J Leukoc Biol 2009; 85:382-90.
39. Christou NV, Meakins JL, Gordon J, et al. The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg 1995; 222:534-46.
40. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003; 3:867-78.
41. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/IL-10 production. J Surg Res 1994; 56:579-85.
42. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009; 101:36-47.
43. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170:1435-44.
44. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50.
45. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952-63.
46. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002; 168:2493-500.
47. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005; 174:3765-72.
48. Patel A, Patel J, Ikwuagwu J. A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010; 65:2697-8.
49. Gaffen SL, Hernandez-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res 2011; 50:181-187.